Rigel Pharmaceuticals announced $58.8 million in total revenues and $8.7 million net income for Q1 2026, driven by a 26% increase in net product sales. The company is progressing its Phase 1b study of R289, targeting lower-risk myelodysplastic syndrome, with dose expansion enrollment expected to complete in H2 2026. Rigel reaffirmed its 2026 revenue guidance of $275-$290 million and anticipates positive net income for the full year while continuing clinical development and business growth.
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
YieldMax ETFs have announced their weekly distributions for Group 1 ETFs, with distribution rates ranging from about 25% to over 65%. These ETFs focus on option income strategies across sectors like semiconductors, AI, crypto, and metals. Investors s...
QTREX Quantum Ltd announced that its Additively Manufactured Electronics (AME) technology achieved a 97% yield validation at a major U.S. interconnect manufacturer. This milestone confirms the technology's readiness for high-demand production environ...
